PT-141 (Bremelanotide)

What it is?

PT-141 is a melanocortin-pathway peptide studied for its role in central arousal and desire signalling. It is positioned to influence libido through CNS mechanisms, rather than relying solely on peripheral vascular modulation.

Dripfy Advantage

• Receptor engagement: Targets melanocortin receptors implicated in sexual motivation and arousal signalling (CNS-focused pathway).
• Neuro-signalling modulation: Associated with regulation of neural circuits linked to sexual response, supporting desire-related endpoints in controlled settings.
• Non-vascular primary mechanism: Positioned as a central-acting approach, distinct from strategies that primarily target blood-flow dynamics.
• Cross-sex applicability: Commonly framed for both male and female sexual wellness research endpoints, depending on protocol design and screening.

Clinical Applications & Therapeutic Potential

• Libido and arousal endpoints: Potential support for improved desire and arousal-response markers in CNS-mediated sexual function protocols.
• Sexual satisfaction outcomes: Potential improvement in sexual satisfaction–related endpoints in appropriately selected cohorts (context-dependent).
• CNS-driven dysfunction frameworks: Positioned for cases where reduced libido is linked to neuro-signalling factors rather than purely mechanical drivers.
• Male and female protocols: Often discussed for broad applicability, with outcomes dependent on baseline neuroendocrine context and protocol controls.

Composition & Formulation

• Peptide Content: 10 mg PT-141 (Bremelanotide)
• Vehicle: Proprietary pH-balanced buffer solution
• Delivery System: Pre-filled, multi-dose, closed-system pen
• Total Volume: 3 mL
• Purity: ≥99% by HPLC/MS